Viatris Will Not Rule Out Symbicort In 2022 As Trial Looms
Q1 Investor Presentation Offers A More Conservative Approach
Facing down a key patent infringement trial beginning on 19 May, Viatris is continuing to eye an opportunity to launch its Breyna generic version of AstraZeneca’s Symbicort before patent expiry in 2023.
